Welcome to our dedicated page for DEVONIAN HEALTH GROUP news (Ticker: DVHGF), a resource for investors and traders seeking the latest updates and insights on DEVONIAN HEALTH GROUP stock.
Devonian Health Group Inc. (TSXV: GSD, OTCQB: DVHGF) is a clinical stage pharmaceutical and biopharmaceutical company that regularly issues news related to its development of prescription drugs for auto-immune inflammatory and fibroinflammatory diseases. As a medicinal and botanical manufacturing company with a focus on prescription botanical drug products, its updates often center on scientific progress, clinical programs and corporate developments.
News coverage for Devonian frequently highlights advances with its lead candidate Thykamine™, the first pharmaceutical product from its SUPREX™ platform. Releases have described comparative in vitro studies against widely used anti-inflammatory drugs, in vivo work in models of MASH and fibrosis, and Phase II clinical data in ulcerative colitis and atopic dermatitis. The company also reports on patent filings, new potential indications and formulation work, such as development of oral forms for gastrointestinal diseases.
Investors and observers can also expect regular financial and corporate news. Devonian publishes quarterly and annual financial results, including commentary on distribution revenues generated by its Altius commercialization subsidiary and on how those revenues support Thykamine™ development. Other announcements cover private placements, stock option grants, changes in officers and directors, shareholder meeting results, option and rights plans, and matters related to financial reporting and exchange approvals.
Because Devonian operates at the intersection of clinical-stage drug development and pharmaceutical distribution in Canada, its news flow combines R&D milestones, regulatory and intellectual property updates, and capital markets activity. Following the DVHGF news stream can help readers track the evolution of its botanical-based pipeline, the status of distribution agreements managed through Altius, and key corporate decisions that shape the company’s long-term strategy.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) has filed a new provisional patent application for the use of Thykamine™ in treating metabolic dysfunction-associated steatotic liver disease (MASLD), specifically MASH. The application is supported by in vivo data demonstrating the potential effectiveness of thylakoid extracts in treating and slowing MASLD progression. This filing represents a strategic move to expand the company's patent portfolio and showcase the broader applications of their technology.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) announced positive preclinical results for Thykamine™ in MASH (metabolic dysfunction-associated steatohepatitis) liver treatment. The study, conducted at SMC Laboratories in Japan, used the STAM mouse model to evaluate Thykamine's effects on liver disease progression.
The results showed that Thykamine™, administered orally at doses of 0.5, 5.0, and 50.0 mg/kg daily for 3 weeks, demonstrated significant hepatoprotective effects. The treatment lowered the NAFLD activity score (NAS) and decreased various markers including α-SMA, collagen types I and III, F4/F80, Ly-6G, and MARCO expression. These effects were comparable to Resmetirom, the first FDA-approved MASH management drug.
The complete MASH preclinical results are planned for publication in 2025.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) announced that its pharmaceutical distribution division, Altius Healthcare Group, received notice that a licensor will not renew the distribution agreement for Dexlansoprazole. This product accounted for 86% of Devonian's total revenues for fiscal year ended July 31, 2024, and 92% for the quarter ended October 31, 2024. The license agreement will terminate on April 17, 2025. The company will continue distributing Pantoprazole Magnesium and Cleo-35® after the termination.
Devonian Health Group announced results from an in vitro comparative study showing Thykamine™ demonstrated superior anti-inflammatory potency compared to current market alternatives. The study, conducted at Université Laval, compared Thykamine™ against various corticosteroids and a phosphodiesterase inhibitor.
The study measured the inhibition of four cytokines (MCP-1, MIP-1α, MIP-1β and RANTES) in LPS-stimulated U937 monocytic cells. Thykamine™ showed significantly higher inhibition potency for MCP-1 (28-136%), MIP-Alpha (30-108%), MIP-1 Beta (39-111%), and RANTES (47-258%, except versus Crisaborole and Prednisone). The results support Thykamine™'s wide-spectrum anti-inflammatory properties and multi-mode action, complementing its previous clinical efficacy in phase 2 studies for ulcerative colitis and atopic dermatitis.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) has appointed Viktoria Krasteva as its new Chief Financial Officer, effective February 17, 2025. Krasteva will replace interim CFO Colette Laurin, who will temporarily remain to facilitate the transition. The new CFO brings approximately 20 years of financial management and strategic leadership experience, particularly in healthcare, technology, and financial markets.
Krasteva is a chartered professional accountant (CPA) with a bachelor's degree in international commerce from the University of World Economy in Bulgaria and graduate degrees in Public Accountancy from Concordia and McGill universities. The appointment comes at what CEO Luc Gregoire describes as a 'pivotal stage' of the clinical-stage 's growth, which focuses on developing solutions for inflammatory diseases.
Devonian Health Group (DVHGF) reported strong Q1 2025 financial results, with distribution revenue reaching $5.85 million, marking a 360% increase year over year. This growth was primarily driven by DEXLANSOPRAZOLE, their exclusive generic drug for GERD in the Canadian market. The company reported a reduced net loss of $0.362 million ($0.002 per share), compared to $0.721 million ($0.005 per share) in the previous year.
The company's cash position strengthened to $12.5 million as of October 31, 2024, up from $9.9 million, while maintaining debt at $2.1 million. Additionally, Devonian granted 1,535,715 stock options to independent directors at an exercise price of $0.19 per share, valid for ten years.
Devonian Health Group reported strong financial results for fiscal year 2024. Fourth quarter revenues surged 749% year-over-year to $9 Million, while annual revenues increased 660% to $17.8 Million. The company posted Q4 net income of $0.007 per share and an annual net loss of $0.008 per share. The growth was primarily driven by its subsidiary Altius Healthcare's DEXLANSOPRAZOLE launch, the only authorized generic in Canada for GERD treatment. Cash position improved to $9.9 million with reduced debt of $2.08 million. The company continues development of ThykamineTM for atopic dermatitis treatment.
Devonian Health Group Inc. (TSXv: GSD), a clinical stage botanical pharmaceutical , has announced the grant of stock options approved by its Board of Directors. The company, which focuses on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, has issued a total of 3,298,611 options to its officers.
The options come with an exercise price of $0.16 and are valid for a period of 10 years from the date of grant. Notably, these options are exercisable immediately upon grant, providing immediate potential value to the recipients. This move may be seen as a strategy to align the interests of the company's officers with those of the shareholders.
Devonian Health Group Inc. (TSXV: GSD; OTCQB: DVHGF) has announced two significant changes:
1. Amendment to Articles of Amalgamation: The company will create a new class of common shares, converting all existing subordinate voting shares into common shares. This reclassification, approved by shareholders on February 20, 2024, is expected to take effect on October 10, 2024. The new common shares will trade under the symbol "GSD" on the TSX Venture Exchange.
2. Management Change: Ms. Colette Laurin, Interim Chief Financial Officer, has resigned effective January 5, 2025. Devonian has initiated a search for her replacement.
These changes aim to simplify the company's share structure and manage a key leadership transition.
Devonian Health Group (TSXV: GSD; OTCQB: DVHGF) has announced its participation in Renmark Financial Communications Inc.'s Virtual Non-Deal Roadshow Series in Chicago on July 17, 2024. The event will feature a presentation by Luc Grégoire, President & CEO of Devonian, covering the company's latest investor presentation followed by a live Q&A session.
Stakeholders, investors, and interested individuals are invited to register for this live event. While registration may be , a replay will be available on the company's investor website after the event. Participants are advised to use the latest version of Google Chrome for optimal connectivity.